Immunotherapy plus chemo shows promise for tough uterine cancer
NCT ID NCT06561308
First seen Dec 11, 2025 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This study is testing whether adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can help shrink advanced endometrial cancer. About 39 women with stage III or IV disease will receive the combination, then undergo surgery. The main goal is to see how many have no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOID ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Women's hospital school of medicine zhejiang university
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Camrelizumab (a PD-1 inhibitor) combined with carboplatin and paclitaxel chemotherapy
What this could lead to
If successful, this combination could become a new standard approach to shrink advanced endometrial tumors before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 39 participants, so results may not apply broadly. The added immunotherapy also carries risks of immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.